PuSH - Publikationsserver des Helmholtz Zentrums München

Kaesmann, L.* ; Khaltar, K.* ; Taugner, J.* ; Mansoorian, S.* ; Richlitzki, C.* ; Hofer, T.P. ; Nößner, E. ; Schulz, C.* ; Unterrainer, M.* ; Tufman, A.* ; Klauschen, F.* ; Jung, A.* ; Kunz, W.* ; Kumbrink, J.* ; Reinmuth, N.* ; Holzgreve, A.* ; Belka, C.* ; Manapov, F.* ; Eze, C.*

Patient-reported versus clinician-reported outcomes in patients undergoing concurrent chemoradiotherapy and durvalumab maintenance for inoperable stage III NSCLC: Insights from the prospective PRECISION Study.

J. Thorac. Oncol. 20:191P (2025)
BackgroundConcurrent chemoradiotherapy (CRT) followed by durvalumab maintenance therapy (D) is the standard treatment for inoperable stage III NSCLC. While clinician-reported outcomes (CROs) standardize treatment assessments, they may not fully reflect patient experiences. This study explored the relationship between patient-reported outcomes (PROs) and CROs during CRT and D.MethodsData from 40 inoperable stage III NSCLC patients undergoing CRT+D were collected prospectively at six predefined time points: before (baseline), during, and after CRT, as well as 3, 6, and 12 months afterward. Patient-reported outcomes (PROs) were assessed using the EORTC QLQ-C30 and QLQ-LC13 questionnaires, while clinical-reported outcomes (CROs) were measured via CTCAE v5.0.ResultsPRO compliance exceeded 95% (n = 229 questionnaires). The baseline mean symptom scores were as follows: cough 40.8 (SD 31.6), dyspnea 26.9 (28.2), chest pain 17.5 (25.4), fatigue 44.7 (27.8), and appetite loss 30 (36.8). The mean physical function and global health status scores were 70 (SD 26.2) and 53.3 (20.4). Estimated mean changes (points) from baseline to 6 and 12 months using a mixed model for repeated measures (MMRM) were: cough 3.0 (95%CI: −5.9 to 11.9) and 9.0 (−0.4 to 18.5); dyspnea 8.1 (2.4 to 13.9) and 5.9 (−1.9 to 11.9); chest pain −1.1 (−8.8 to 6.6) and 3.6 (−4.7 to 11.9); global health 1.9 (−3.6 to 7.4) and 3.1 (−2.8 to 8.9). Cronbach’s alpha indicated poor consistency between the corresponding QLQ-C30, QLQ-LC13, and CTCAE items: dyspnea (QLQ-C30) vs. CTCAE 0.57; dysphagia (QLQ-LC13) vs. CTCAE 0.56; dyspnea (QLQ-LC13) vs. CTCAE 0.52; and coughing (QLQ-LC13) vs. CTCAE 0.49.ConclusionsSymptom scores remained low throughout therapy, consistent with the PACIFIC trial results, which showed no deterioration in PROs. The discrepancies between PROs and CROs emphasize their complementary nature, as PROs capture subjective experiences and CROs focus on clinical parameters. These gaps underline the need for enhanced communication, better measurement tools, and increased attention to patient needs, reinforcing the significance of PROs in patient-centered care. Clinical trial identification: NCT05027165.
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Meeting abstract
ISSN (print) / ISBN 1556-0864
e-ISSN 1556-1380
Zeitschrift Journal of thoracic oncology
Quellenangaben Band: 20, Heft: 3, Seiten: , Artikelnummer: 191P Supplement: ,
Verlag Elsevier
Verlagsort New York, NY
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
Förderungen AstraZeneca